menu
    • menu
    [{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles Vaccines \/ The EU Malaria Fund"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/ Univercells"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dompe Farmaceutici

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid...

                            Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Achilles Vaccines

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Achilles Vaccines

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Malaria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : The EU Malaria Fund

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fi...

                            Details : The investment supports development of a novel Malaria vaccine on Achilles versatile technology platform to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. To also supports produce low-cost, safe and self-adjuvanting fit-for-purpose...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 19, 2020

                            Lead Product(s) : Malaria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : The EU Malaria Fund

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ReiThera

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ReiThera

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adenoviral Vector-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Univercells

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based CO...

                            Details : The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 23, 2020

                            Lead Product(s) : Adenoviral Vector-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Univercells

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Takis Biotech

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Takis Biotech

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linear DNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinic...

                            Details : The vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 18, 2020

                            Lead Product(s) : Linear DNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Janssen-Cilag

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Janssen-Cilag

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telaprevir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

                            Details : Telaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2012

                            Lead Product(s) : Telaprevir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth